All News

Lknee.OA_.jpg

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

RheumNow

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.

Among patients enrolled in CANTOS, the pooled incidence rate for total hip replacement/total knee replacement was 0.31 events per 100 person-years for those receiving the monoclonal antibody every 3 months for up to 5 years compared with 0.54 per 100 for those given placebo, according to Paul M. Ridker, MD, of Harvard Medical School in Boston, and colleagues.

Read Article
podcast logo

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
backpain.hip_.jpg (keep)

Cosentyx FDA Approval for Non-Radiographic Axial Spondyloarthritis

Jack Cush, MD

Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab. 

Read Article
List.jpg (keep)

Day 4 - Top 3 from EULAR 2020

Jack Cush, MD

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
Dr. D. Minna @UTSWNews rheum grand rounds: review of OA: 1. Exercise may increase cartilage volume 2. Osteophytes are an adaptation to mechanical stimuli rather than a degen. process (no correl w/cartilage volume) 3. Hallmark of OA is abn. matrix turnover @RheumNow

k dao KDAO2011 ( View Tweet)

RA is associated with a 24‐35% lower risk of type 2 diabetes. Claims data comparison of 449,327 RA, general non‐RA, hypertension, OA, or PsA patients finds a lower risk of T2DM in RA (7/1000PY) and highest w/ HTN (12.3/1000PY) https://t.co/uZn5qaImO9

Links:

Dr. John Cush RheumNow ( View Tweet)

Full read clinical practice guideline on obesity management from the Canadian Medical Assn Journal. https://t.co/YdbjtnBcST

Links:

Dr. John Cush RheumNow ( View Tweet)

Virtual Video Joint Exam Pearl #5: The worst/most ineffective Virtual visits done with the Patient (or MD) driving in their CAR for the virtual visit!! Amazingly I have had a half dozen of these & requested the patient pull over so I could deliver a rheum Citation.

Dr. John Cush RheumNow ( View Tweet)

Virtual Video Joint Exam Pearl #3: Despite cam setups designed to do upper extremity exams, patients can easily move cams and limbs to examine spinal movt, gait, knee, ankle and foot problems with great accuracy.

Dr. John Cush RheumNow ( View Tweet)

Fracture risk & prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional comparison of 52 myositis and 43 RA pts. OP Prevalence higher in the myositis group (13.5% v 7%) but equal fracture risk (68 v 75%) https://t.co/XT6O9HoqdH

Links:

Dr. John Cush RheumNow ( View Tweet)

Platelet Rich Plasma Versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis: a Meta-Analysis of 26 randomized controlled trials #osteoarthritis #knee #PRP #HA metanalysis favours PRP! https://t.co/Z5Olucs3ku

Links:

Peter Nash drpnash ( View Tweet)

FDA has issued draft guidance on Cannibis research: “Cannabis & Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” outlines FDA’s current thinking on clinical research related cannabis-derived compounds https://t.co/ppvisN1oxU

Links:

Dr. John Cush RheumNow ( View Tweet)

Bisphosphonate therapy may be protective against radiographic knee OA progression in early‐stage patients (KL grade < 2) (HR 0.53), especially non-obese. Study from 1977 women in the Osteoarthritis Initiative. https://t.co/tZhovfMWTh

Links:

Dr. John Cush RheumNow ( View Tweet)

The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets https://t.co/IWbiVw9PSP

Links:

Victoria Shanmugam VickiShanmugam ( View Tweet)

Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM

Links:

Dr. John Cush RheumNow ( View Tweet)
Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM

Links:

Dr. John Cush RheumNow ( View Tweet)
2000–2016, analgesic use for OA has changed in UK. Oral NSAIDs Rx decreased & other analgesics/opioids increased (P < 0.001). Pts w/ GI dz likely to recv topical NSAIDs, tylenol, opioids. Opioids moreso in elderly, women, obesity, smokers, comorbidities. https://t.co/AJiWUAycLb

Links:

Dr. John Cush RheumNow ( View Tweet)

Fasinumab, nerve growth factor inhibitor, studied in a phase II trial of 421 moderate-to-severe OA (knee or hip) pts x36 wks & show to be better than placebo. But FAS had more AE (17% v 10%), Jt Surgeries (7% v 1%) and destructive arthropathy in 1 FAS pt https://t.co/eHvYrByF1Z

Links:

Dr. John Cush RheumNow ( View Tweet)

A negative RCT shows yearly treatment with Zolendronic acid fails to change tibiofemoral cartilage volume (by MRI) in Knee Osteoarthritis patients with bone marrow lesions. 223 knee OA pts recv ZOL vs PBO x24 mos , w/ no change inVAS pain (-11.5 vs -16.8) https://t.co/N7N0rL8iCX

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2020 #op0327 AI stages knee OA radiograpgic chsnges ieth accuracy 91.8-99% in 95% of the cases. Would you prefer AI or human radiology readings for MSK imaging ? @RheumNow

Olga Petryna DrPetryna ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×